Science – Page 34 – International Cannabis Business Conference

Study Finds No Link Between In-Utero Cannabis Exposure And Elevated Risk Of ADHD In Children

Written by Frank Schuler on August 29, 2022. Posted in Science.

Few topics, if any, in the cannabis world are as sensitive as cannabis use during pregnancy, for obvious reasons. An expecting mother that consumes cannabis may be the most stigmatized type of cannabis consumer on earth.

If an expecting mother is suspected of consuming cannabis in any form in any manner, they run the risk of being put into a system that will likely have no mercy, and that is unfortunate for many reasons.

To be clear, I am not advocating for cannabis consumption during pregnancy. I am pointing out the obvious public health issues that arise from expecting mothers living in fear, and as a result, presumably being less-than-candid with their doctor(s) due to the fear of possible prosecution and/or eventually being separated from their child.

The fact of the matter is that some expecting moms consume cannabis for various reasons, often for medical reasons via smokeless consumption methods, and they should feel free to talk to their doctors about it in order to receive the best medical advice possible for themselves and their baby.

As with all things cannabis, science should lead the way and political hype and fearmongering should be avoided. Fortunately, cannabis use during pregnancy is being researched more often as cannabis reform spreads, with a recent example of that coming out of Canada. Below is more information about it via a NORML news release:

Quebec, Canada: Prenatal cannabis exposure is not associated with an increased risk of attention deficit disorders among children, according to data published in the journal BMJ Open.

Canadian investigators evaluated the relationship between in-utero marijuana exposure and attention deficit with or without hyperactivity disorder in a cohort of 2,408 children.

Researchers reported “no significant association” between either occasional or regular prenatal cannabis exposure and ADHD after adjusting for potential confounders.

“In our study, we did not find any association between in-utero occasional or regular exposure to cannabis and the risk of ADHD in children, as well as overall exposure to cannabis and the risk of ADHD in children,” authors concluded. “Further research focusing on the timing of exposure during pregnancy (e.g., first, second, third trimester), as well as using different methods for quantifying prenatal cannabis exposure (e.g., biological samples), is needed to better understand the impact of cannabis use during pregnancy and developmental outcomes in children.”

Full text of the study, “Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort,” appears in BMJ Open. Additional information is available from NORML’s fact sheet, “Maternal Marijuana Use and Childhood Outcomes.”

Cannabis Industry Leaders And International Policymakers To Attend Croatia Retreat

Written by Johnny Green on August 22, 2022. Posted in Business, Entertainment, Policy, Science.

After a historic Global Investment Forum and B2B conference in Berlin in July, the International Cannabis Business Conference is hosting a Mediterranean retreat in Rovinj, Croatia at the stunning 5-star Grand Park Hotel on September 22-23, 2022.

“It’s a critical time for the international cannabis industry, including for the Balkan region. The emerging legal cannabis industry is expanding at an ever-increasing pace in virtually every corner of the planet right now. It’s extremely important for industry leaders and policymakers from around the world collaborate.” stated Alex Rogers, founder of the International Cannabis Business Conference.

“The cannabis industry is going global, and in order for the industry to reach its full potential and provide numerous benefits to society it is vital for leaders to meet, network, brainstorm, and compare ideas. That is why we created the retreat in Croatia. The retreat will certainly contain some of the elements that our events are famous for, however, it will be in a more intimate setting so that leaders from dozens of countries can dive deeper into the more granular aspects of creating the next great global industry.” Rogers went on to say.

Cannabis reform is spreading across the European continent. With Germany expected to launch a regulated adult-use industry in the near future, every European nation is trending closer to reforming its own cannabis laws, including Balkan nations. The Balkan region is already home to a number of ancillary industries that would greatly benefit from cannabis reform, including and especially the scientific research industry.

The International Cannabis Business Conference’s Mediterranean retreat in Croatia will be unlike any other cannabis event to-date. The retreat will feature a blend of education and networking, with topics for the retreat’s curriculum to include:

Current legalization efforts in Europe
Economic benefits of regulating cannabis
Embracing cannabis research
Product development for an international market
Sustainable industry strategies
Educating medical professionals
Reforming Balkan region cannabis policies
Raising capital for Balkan cannabis markets

Individual speakers and panelists have already been announced, with more expected to be announced in the near future. Of course, it would not be an International Cannabis Business Conference event without an after-party, and this particular event’s after-party will be unmatched. The one and only DJ Muggs will provide the music for the poolside after-party at the 5-star Grand Park Hotel to cap off a productive and historic retreat.

The International Cannabis Business Conference is the leading B2B cannabis event series on earth. Events have been held in the United States, Canada, Spain, Germany, and Switzerland. Additional locations in other countries are being identified and will be announced in the future.

International Cannabis Business Conference events are attended by leading policymakers, executives, and entrepreneurs from all over the world, with over 85 countries being represented at previous events.

You can secure your spot now and take advantage of the early bird pricing discount.

###

About the International Cannabis Business Conference

The International Cannabis Business Conference is Europe’s longest-running and largest industry B2B tradeshow and conference series. For more information, including how to register for upcoming International Cannabis Business Conference events, please visit: Internationalcbc.com. Find out more on LinkedIn, Twitter, Facebook, YouTube, and Instagram.

For more information or media inquiries, please email noelle@internationalcbc.com or call 541.864.0090.

pain-menopause-menstrual-cycle-urilogical-cancer pain-menopause-menstrual-cycle-urilogical-cancer

Prior Cannabis Use Inversely Associated With Urological Cancers

Written by Frank Schuler on August 21, 2022. Posted in Science.

Urological cancers can occur in both men and women and are caused by abnormal cell growths in the organs of the urinary tract and the male reproductive tract.

The specific types of urological cancers can affect the kidneys, ureter, bladder, urethra, prostate, and/or testicles. The most common type of urologic cancer is bladder cancer.

Various things can contribute to the development of urological cancers, including genetics and environmental factors, with tobacco use being a notable contributing factor.

Common treatments include surgery, radiation, chemotherapy, and in some cases immunotherapy. Past cannabis use is associated with a lower risk of urological cancers according to a new study. Below is more information about it via a news release from NORML:

London, United Kingdom: Women with a past history of cannabis use are at lower risk of suffering from certain types of urological cancers, according to population-based data published in the journal Cancer Medicine.

An international team of researchers from China, France, and the United Kingdom assessed the relationship between cannabis use and cancer risk in a cohort of more than 151,000 subjects.

Investigators reported, “Previous use of cannabis was a significant protective factor” in women against renal cell carcinoma (RCC) and bladder cancer (BCa). They further reported that “previous cannabis use was a significant protective factor for PCa (prostate cancer) in men with a history of tobacco smoking.” A history of cannabis use had a null effect on rates of testicular cancer.

Authors concluded: “In the current study, we investigated the association between the use of cannabis and the risk of urological cancers. We observed that: (1) previous use of cannabis was a significant inverse association with both RCC and PCa; (2) cannabis use was associated with the lower risk of BCa in the point estimates; (3) the protective effect of cannabis on RCC and BCa was significant for females but not for males; (4) cannabis use had a causal effect on lower incidence of RCC.”

Prior studies have similarly identified an inverse association between a past history of cannabis use and the development of certain types of cancers, including bladder cancer, liver cancer, and head and neck cancers.

Full text of the study, “Association between cannabis use with urological cancers: A population-based cohort study and mendelian randomization study in the UK biobank,” appears in Cancer Medicine.

Spanish General Counsel Of Official Colleges Of Physicians Plans To Train Doctors In Cannabis Care

Written by Marguerite Arnold on August 15, 2022. Posted in Policy, Science.

The formal approval of cannabis for medical purposes in Spain has created a demand to train doctors in prescribing medical cannabis

The Spanish General Council of Official Colleges of Physicians has announced plans to train doctors to prescribe medical cannabis. This endeavor however is not something specific to cannabis reform, but rather incorporates cannabis into already existing training programs for new medicines in general.

There is no date set for the initiation of the new program.

The Urgent Need for Doctor Training and Education

The need for doctors who understand how to administer cannabis as medicine has never been more urgent. As recreational reform how hangs in the balance in multiple European countries, how the drug interacts with the human body is an issue that still needs to be better understood – no matter the intention of the user.

There are several reasons for this. The first is, of course, medical. Most mainstream physicians do not understand how to administer cannabis – and specialists tend to err on the side of extreme caution – leaving many medical users without enough medicine. The additional issues include ending discrimination that still exists against medical cannabis users – such as prohibiting them from receiving organ transplants – to understanding how cannabis interacts with the human body.

The second reason, however, is clearly because additional reform is on the way. “Recreational users” will mushroom across Europe – many of whom are actually patients but do not realize it.

The Status of Cannabis Legalization in Spain

Spain pioneered the idea of cannabis clubs – the model for which has shown up internationally – and most notably, in South Africa. For the past decade, clubs have been established across the country and are now present in most Spanish cities. Barcelona remains the centre of club culture and where most of the country’s clubs are located.

Beyond this, Spain has issued five licenses for medical cultivation at a federal level, the last being issued just this year.

In addition, hemp cultivation is legal across the country – but only for industrial use.

The formal recognition of medical cannabis is an important step here – but it clearly won’t be the last. Training doctors in cannabis care is an important part of the process to normalize the use of the plant as a medicine.

CBD Is Safe And Effective For People With Treatment-Resistant Anxiety Disorders Per Clinical Trial

Written by Frank Schuler on August 15, 2022. Posted in Science.

It is estimated that roughly 4% of the world’s population suffers from some level of anxiety, although, no one really knows the actual number. The condition often goes undiagnosed for various reasons, so it’s quite possible that the rate is much higher.

Anxiety involves intense, excessive, and persistent worry and fear about everyday situations. Physical symptoms can include a fast heart rate, rapid breathing, sweating, and fatigue.

Many of the pharmaceutical medications that are commonly prescribed for anxiety involve a laundry list of terrible side effects. Some cases of anxiety are so bad that pharmaceutical treatments don’t even work.

Fortunately, CBD may be able to help in those cases. Below is more information about it via a news release from NORML:

Melbourne, Australia: The adjunctive use of CBD safely and effectively reduces severe anxiety in young people, according to clinical data published in The Journal of Clinical Psychiatry.

Australian researchers assessed the daily administration of CBD in a cohort of 31 young people (ages 12 to 25) with refractory anxiety. Participants self-titrated their daily doses of CBD (between 400 mgs and 800 mgs) over a 12-week period.

CBD dosing was associated with a “statistically significant reduction in anxiety severity,” as measured on the Overall Anxiety Severity and Impairment Scale (OASIS). CBD dosing also “demonstrated an acceptable safety profile, with no serious adverse events reported and no clinically significant deviations to blood cell counts.”

Investigators reported, “Approximately 40 percent of all participants experienced a 50 percent reduction in OASIS score, and two-thirds experienced a 33 percent reduction.” They added, “By the end of treatment, the number of participants rated as markedly or severely ill had decreased from 17 (56.7 percent) to 5 (16.7 percent).”

Authors acknowledged that CBD’s greatest efficacy was observed during the final four weeks of treatment, indicating that a longer treatment regimen may potentially lead “to even greater improvements.”

They concluded: “Given that the patients included in our trial were some of the most severe and treatment resistant and had significant functional impairment and multiple failed treatment attempts, the reduction in anxiety severity observed here suggests that CBD has clinically meaningful anxiolytic effects. … The findings of this trial suggest that further investigation of CBD for anxiety in conjunction with usual care is warranted.”

Other human trials evaluating the use of CBD for anxiety have yielded inconsistent results. A 2019 placebo-controlled trial reported that daily CBD intake reduces symptoms of social anxiety disorder in teens, whereas a 2022 study determined oral doses of CBD to be ineffective at reducing symptoms of moderate-to-severe testing anxiety in college students. A 2018 Brazilian study reported that the consumption of 300mg of CBD significantly reduced anxiety due to public speaking, but that higher (600mg) and lower (150mg) had no effect.

Full text of the study, “Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial,” appears in The Journal of Clinical Psychiatry.

stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital stethoscope doctor medical hospital

Authorized Medical Cannabis Patients At Low Risk For Psychiatric Hospitalizations

Written by Frank Schuler on August 15, 2022. Posted in Science.

If you sit and listen to a cannabis prohibitionist talk for a long enough duration of time it’s almost guaranteed that they will offer up the talking point that ‘cannabis makes you crazy.’

They may not say it in those exact words, however, that is the sentiment of virtually any talking point by a cannabis prohibitionist that involves consuming cannabis and mental health.

Prohibitionists act as if a person taking one hit off of one joint is enough to instantly thrust that person into a mental health abyss. Fortunately, that is not the case, as evidenced by a recent study in Canada. Below is more information about it via a news release from NORML:

Quebec, Canada: Authorized medical cannabis patients are at low risk for psychiatric hospitalizations resulting from their marijuana use, according to data published in the journal Substance Use & Misuse.

Canadian researchers assessed marijuana-related hospitalizations among a cohort of over 23,000 authorized medical cannabis patients. (Canada has legalized the use of cannabis products for both medical purposes and for adult use.) Specifically, investigators tracked incidences of hospitalizations attributable to either “cannabis poisoning” or because of “mental or behavioral disorders due to the use of cannabis.” Patients in the study were tracked for a median of 240 days.

During the course of the trial, investigators reported that a total of 14 patients were hospitalized for issues related to cannabis toxicity and 26 were admitted for either mental or behavioral disorders. The findings push back against high-profile claims from some cannabis reform opponents that frequent marijuana exposure is a trigger for psychosis and other mental health disorders.

“The results suggest that the incidence of cannabis poisoning or cannabis-related mental or behavioral disorders was low among patients who were authorized to use cannabis for medical care,” authors concluded. “Our observation of small rates of ED visits and hospitalization for cannabis poisoning and CUDs [cannabis use disorders] among this large cohort of medical cannabis users helps address concerns regarding increasing use of medical cannabis.”

Full text of the study, “Incidence and predictors of cannabis-related poisonings and mental and behavioral disorders among patients with a medical cannabis authorization: A cohort study,” appears in Substance Use & Misuse. Additional information on cannabis and mental health is available from NORML’s white paper, ‘Cannabis, Mental Health, and Context: The Case for Regulation.

Fibromyalgia pain doctor hospital Fibromyalgia pain doctor hospital

Cannabis May Be A “Useful Treatment Strategy” For Fibromyalgia Patients

Written by Frank Schuler on August 7, 2022. Posted in Science.

Fibromyalgia is a serious problem across the globe, affecting people of all ages. It is estimated that as many as one out of every twenty people on earth suffer from the condition to some degree.

According to Mayo Clinic, “Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.”

Unfortunately, there is currently no known cure for fibromyalgia, however, researchers in Canada have found evidence that medical cannabis can be an effective treatment for some patients. Below is more information about it via a news release from NORML:

Montreal, Canada: Cannabis products are associated with symptom relief among fibromyalgia (FM) patients, according to data published in the journal Arthritis Care & Research.

Canadian researchers assessed the efficacy of medical cannabis products (flower or extracts) over a one-year period in a cohort of patients with FM. Investigators assessed patients’ levels of pain intensity, sleep quality, and depression/anxiety every three months. All of the subjects enrolled in the study were qualified to use medical cannabis products by their general practitioner.

Consistent with other studies, researchers reported an association between the consumption of medical cannabis and improvements in subjects’ sleep, depression/anxiety, and pain – with the greatest reduction in pain intensity (a mean decrease of 1.7 points on a zero to 10 scale) occurring within the first six-months of treatment.

Authors reported: “Our current findings are consistent with observations of pain relief, improved sleep, and alleviation of symptoms of anxiety and depression in other studies among patients with chronic pain using medical cannabis. Although preliminary, our findings suggest that improvements in negative affect and sleep might represent potential mechanisms of action underlying pain reductions among FM patients who are using medical cannabis.”

They concluded, “Medical cannabis may present a useful treatment strategy for patients with FM in light of an effect on the triad of symptoms of pain, negative affect, and sleep disturbances.”

Survey data reports that fibromyalgia patients frequently consume cannabis for therapeutic purposes. A recent review of the relevant literature concluded, “[T]he use of cannabinoids and cannabis carries limited side effects in the treatment of FM, and they can also improve some common and debilitating symptoms associated with FM, thus making them an adequate potential treatment option, when other treatment lines have been exhausted.”

Full text of the study, “Predictors of pain reduction among fibromyalgia patients using medical cannabis: A long-term prospective cohort trial,” appears in Arthritis Care & Research. Additional information on cannabinoids and FM is available from NORML.

hemp-cannabis-flower-plant-garden-outdoor hemp-cannabis-flower-plant-garden-outdoor

Hemp Increases Cow Health – and Reduces Bovine Stress

Written by Marguerite Arnold on August 1, 2022. Posted in Science.

A federally funded study published in Scientific Reports suggests that hemp has similar effects on humans and cows

A US Department of Agriculture-funded study of hemp-based cattle feed, which has been underway since 2020 has begun to deliver intriguing results. Cows can completely digest all parts of the hemp plant, including stems, stalks, and other “waste” parts not used for other purposes.

Giving industrial hemp to cows appears to help them feel less stressed and may even be good for their overall health. The effects of the plant, in other words, may be similar in both humans and cattle. Furthermore, this is a very efficient use of parts of the hemp plant that are not normally used – creating a highly efficient end-use product.

This study examined 16 Holstein steers, split into two groups. One group was fed nothing more than their normal feed for a period of two weeks. The other group consumed their feed, mixed with hemp that gave each cow a daily dose of 5.5 mg of cannabidiolic acid per kilo of body weight. Blood samples were taken from all cows to understand how hemp affected each study participant.

The cows that ate CBD began to show lower cortisol and prostaglandin levels in their blood. Both of these chemicals are common markers of stress. They also spent more time lying down than the control group.

Cows who suffer elevated levels of stress, either from early weaning or cramped quarters, are more prone to developing respiratory infections or other diseases.

Despite these encouraging results, American farmers are still not allowed, by mandate of the USDA, to feed hemp to any livestock bound for human consumption. The reason is that the US government is still concerned that minute amounts of THC might linger in meat or milk from cows who have consumed the hemp plant. This latest study shows that these concerns are not valid.

Animals and Hemp

While still in its early stages, feeding animals hemp and hemp products is clearly a growth industry. Multiple studies have been conducted on dogs, with good effect. Beyond domestic animals, however, farm animals also are positively affected. A recent Thai study has found that chickens who are fed hemp-based food also need fewer antibiotics to stay healthy.

As more conclusive studies are conducted, it is becoming apparent that cannabis is not just a wonder plant for people, but for all kinds of animals as well.

International Cannabis Business Conference Berlin 2022 Registration International Cannabis Business Conference Berlin 2022 Registration

Recapping A Historic International Cannabis Business Conference In Berlin

Written by Johnny Green on August 1, 2022. Posted in Business, Entertainment, Policy, Science.

Whether you are a passionate cannabis enthusiast or just a passive cannabis industry observer, you are surely well aware of the fact that Germany is trending towards implementing adult-use cannabis legalization, and with it, a regulated adult-use industry. Germany may not be the first nation to pursue such a nationwide public policy and industry evolution, however, it is the most significant effort of its kind to date.

Germany is home to the fourth-largest economy on planet earth, with only the economies of the United States, China, and Japan ranking higher (as measured by GDP). Cannabis may be legal at the state level in some parts of the U.S., yet federal legalization still remains out of sight and nationwide cannabis sales are even further out of reach. China and Japan have no current plans to legalize cannabis, and for that matter, the rest of the countries on the list of ‘top ten economies on earth’ will maintain prohibition for the foreseeable future with the exception of Canada.

Canada is currently the only G-7 nation that allows regulated adult-use sales and has served as the top ‘legal cannabis economy’ on the planet since launching nationwide adult-use sales in late 2018. Once Germany launches nationwide cannabis sales, which could come as early as 2023, it will instantly take over the title of being home to the largest cannabis market in the world.

Germany’s economy is over twice the size of Canada’s economy, and the same is true when comparing the two nations’ populations. Canada only shares a physical border with one country, the United States, and many border states now have their own adult-use industries. Germany, on the other hand, shares physical borders with nine countries – the most in Europe. Barring any unforeseen policy changes, Germany will be an adult-use sales oasis in the region to a large extent, with Germany and the surrounding countries’ populations adding up to roughly a quarter billion people. The significance of legalization in Germany cannot be overstated.

Given the context of what is going on in Germany right now, Berlin served as an amazing backdrop to the International Cannabis Business Conference which took place on July 19-20th at the Hotel Estrel. It was the fifth installment of the B2B conference in Berlin, the largest of its type in Europe, and with so much excitement about what is going on right now in Germany, it proved to be an experience of a lifetime.

The attention of virtually every member of the emerging global cannabis industry has been squarely on Germany this year, and it was very evident throughout the conference that the excitement level was off the charts with so many people finally meeting in person to discuss everything. You could really sense that everyone was eager to get back to attending events in person, to learn more about what is going on in Germany and Europe, and to share what is going on in their own respective jurisdictions.

A major theme of this year’s historic conference involved cohorts representing over 85 countries traveling to the event, creating almost a ‘United Nations of cannabis’ environment. One thing that we have always strived to do at the International Cannabis Business Conference is to connect people from all over the globe, and it was exciting to see that on full display at this year’s Berlin conference on such a grand scale.

Germany, for obvious reasons, is a very exciting place for cannabis and what is going on there will have a butterfly effect on the rest of the world. However, there is plenty of other significant things happening elsewhere on the planet, and that was evident in much of the networking that occurred throughout the two-day B2B conference. Entrepreneurs, policymakers, investors, and industry service providers from nearly every corner of the world were comparing notes, striking deals, and discussing plans for the future.

It was very inspiring to see each and every time, and it was truly symbolic of the current state of the cannabis industry. The cannabis industry is going global. Historically, legal cannabis markets were entirely confined by national borders. Exports and imports have slowly ramped up in some nations over time, but make no mistake – the future of the cannabis industry will largely play out on the world stage and the cannabis plant is going to go mainstream at a global level in the coming years, which was talked about over and over at the Berlin conference by participants in discussions that often included representatives from multiple continents.

The most historic moment of the conference, and arguably the most historic moment of any cannabis conference to date, came via the day one keynote address provided by Mr. Burkhard Blienert. Mr. Blienert currently serves as Germany’s top drug policy official and is overseeing the nation’s adult-use cannabis legalization and industry implementation process. It is the first time in history that a currently-serving official at that level has ever spoken at a cannabis conference, and right in the middle of the public policy reform process no less. Hearing from Mr. Blienert in the midst of everything that is going on in Germany and Europe was truly special and an experience that attendees will no doubt cherish for years to come.

The two-day conference was packed with other world-class speakers and panels, videos of which can be found on the International Cannabis Business Conference YouTube channel. Topics for panels and presenters included, but are not limited to:

Ongoing activism and advocacy
Medical cannabis policy
Cannabis policy in Germany
Shifting cannabis policies in Europe
Evolving industry standards and regulations
Emerging markets
Supply chain and logistics
Legalization models
Cultivation
Sustainability
Consumer trends
Investing opportunities

If you have been involved in cannabis for any significant duration of time, then you know firsthand that there are certain times and places when you realize that you are in the midst of history being made. For people in attendance at the International Cannabis Business Conference B2B event in Berlin this summer, it was absolutely one of those times. The networking and learning opportunities were unmatched, and never before has such a wide array of cannabis industry representatives from so many different countries come together under one roof at the same time.

As always, it isn’t an International Cannabis Business Conference event without an amazing after-party, and this year’s after-party was particularly epic. Multi-Grammy awarding-winning reggae band Morgan Heritage kicked off their European tour at this year’s after-party event in Berlin. They were joined on stage by reggae pioneer Rocker-T, and collectively they rocked the house. The concert in such an intimate setting was the perfect way to unwind and celebrate after networking and learning. International Cannabis Business Conference founder Alex Rogers also rocked the mic on stage with the crew for a time, proving once again that the International Cannabis Business Conference works hard and plays hard.

The International Cannabis Business Conference team is already working hard on the next conference in Berlin which is currently slated to take place June 29-30, 2023. It’s quite possible that it could be the first conference in the new adult-use legalization era in Germany, which is an extremely exciting thought. With so much going on in the emerging global cannabis industry right now, particularly in Europe, the 2023 conference in Berlin is a must-attend. We look forward to seeing you there!